Skip to Content

Edarbyclor Approval History

FDA Approved: Yes (First approved December 20, 2011)
Brand name: Edarbyclor
Generic name: azilsartan medoxomil and chlorthalidone
Dosage form: Tablets
Company: Takeda Pharmaceutical Company Limited
Treatment for: High Blood Pressure

Edarbyclor (azilsartan medoxomil and chlorthalidone) is a fixed-dose combination of an angiotensin II receptor blocker (ARB) and a diuretic, indicated for the treatment of hypertension.

Development History and FDA Approval Process for Edarbyclor

DateArticle
Dec 20, 2011Approval FDA Approves Edarbyclor (azilsartan medoxomil and chlorthalidone) for the Treatment of Hypertension

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide